Reata Pharmaceuticals, Inc.
RETA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $1,380 | $958 | $4,167 | $6,218 |
| - Cash | $42 | $590 | $818 | $664 |
| + Debt | $119 | $136 | $0 | $155 |
| Enterprise Value | $1,457 | $504 | $3,349 | $5,708 |
| Revenue | $2 | $11 | $9 | $27 |
| % Growth | -80.7% | 27.4% | -66% | – |
| Gross Profit | $2 | $11 | $9 | -$98 |
| % Margin | 100% | 100% | 100% | -369.1% |
| EBITDA | -$269 | -$244 | -$232 | -$278 |
| % Margin | -12,140.1% | -2,119.3% | -2,575.9% | -1,048.5% |
| Net Income | -$312 | -$297 | -$248 | -$290 |
| % Margin | -14,075% | -2,588.2% | -2,747% | -1,094.3% |
| EPS Diluted | -8.59 | -8.19 | -7.35 | -9.54 |
| % Growth | -4.9% | -11.4% | 23% | – |
| Operating Cash Flow | -$204 | -$236 | -$322 | -$251 |
| Capital Expenditures | -$3 | -$1 | -$1 | -$3 |
| Free Cash Flow | -$208 | -$237 | -$323 | -$254 |